Takeda Biopharmaceuticals India Pvt. Ltd. today announced that the Drug Controller General of India (DCGI) has granted market authorization for QDENGA (TAK-003), making it the first dengue vaccine approved in India for the prevention of dengue disease in individuals aged 4–60 years. The approval marks a significant milestone in India’s fight against dengue, a disease that continues to pose a major public health challenge. Designed to protect against all four dengue virus serotypes, QDENGA can be administered regardless of prior dengue exposure and does not require pre-vaccination testing.
“Dengue is a growing public health challenge, and India needs sustained, evidence-based prevention,” said Dr. Mahender Nayak, Head of Intercontinental Markets, Takeda. “The approval of QDENGA marks an important step forward in strengthening dengue prevention in India, and we remain committed to working with public health authorities, healthcare professionals and partners to support equitable and sustainable access.” Peter Streibl, General Manager, Southeast Asia and India Cluster, Takeda, said dengue is a shared regional challenge that requires collaboration across governments, healthcare professionals and communities to strengthen prevention through sustainable, evidence-based solutions.
Dr. Goh Choo Beng, Medical Affairs Head, Southeast Asia & India Cluster, said India carries a substantial dengue burden, with all four virus serotypes co-circulating in several regions. He noted that QDENGA is designed to protect against all four serotypes, regardless of prior exposure, complementing broader public health measures to strengthen dengue prevention. QDENGA is now approved in 43 countries, has received WHO prequalification, and more than 32 million doses have been distributed globally through public and private immunization programmes.
